Screener
Jazz Pharmaceuticals JAZZ Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Accrued liabilities | 1,022.4 | 1,034.2 |
| Current portion of long-term debt | 1,030.5 | 1,029.9 |
| Income taxes payable | 93.7 | 56.3 |
| Total current liabilities | 2,246.6 | 2,242.5 |
| Long-term debt, less current portion | 4,324.2 | 4,328.4 |
| Operating lease liabilities, less current portion | 47.3 | 50.9 |
| Deferred tax liabilities, net | 547.7 | 594.5 |
| Other non-current liabilities | 161.5 | 124.4 |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's total current liabilities?
- Jazz Pharmaceuticals (JAZZ) reported total current liabilities of $2.25B in Q1 2026.
- How has Jazz Pharmaceuticals's total current liabilities changed year-over-year?
- Jazz Pharmaceuticals's total current liabilities increased by 83.8% year-over-year, from $1.22B to $2.25B.
- What is the long-term trend for Jazz Pharmaceuticals's total current liabilities?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's total current liabilities has grown at a 28.0% compound annual growth rate (CAGR), from $653.75M to $2.24B.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Jazz Pharmaceuticals's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude